https://www.selleckchem.com/pr....oducts/epacadostat-i
Great expectations have been set around the clinical potential of regenerative and reparative medicine in the treatment of cardiovascular diseases (i.e., in particular heart failure [HF]). Initial excitement, spurred by encouraging preclinical data, resulted in a rapid translation into clinical research. The sobering outcome of the resulting clinical trials suggests that preclinical testing may have been insufficient to predict clinical outcome. Number of barriers for clinical translation include the inherent variability
Like
Comment
Share
